

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

01/07/2021 – 30/09/2021

NSW Office for Health and Medical Research





Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised between 1st of July 2021 and 30th of September 2021. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Change benchmark to measure Total Time rather than time spent with LHD Research Office alone
- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> • Study Type = All • Application Type = Greater than low risk • Approval Type = Approved within the reporting period
Exclusions	<ul style="list-style-type: none"> • Application Type = Low and negligible risk • Approval Type = Not within the reporting period • Migrated studies

Total Time:

Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary:

Ethics review performance of NSW HRECs according to the **<90-day benchmark** for studies approved between 01/07/2021 and 30/09/2021 (Quarter 3 2021) are shown in **Table 1**. In Quarter 3 2021, **304 studies** (greater than low risk pathway) were approved by an HREC with an average review time (total time) of **75 days**. Of these 304 studies, **91 (30%)** were classified as clinical trials (**Table 2**). Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3 (by NSW PHOs)** and **Table 4 (by quarter)**. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Table 1. The 90 calendar days benchmark for approval of human research ethics applications (greater than low risk) between 01/07/2021 – 30/09/2021

NSW PHOs		Ethics Approval (Q3 2021)					
		All greater than low risk applications					
		Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
Count <90 Day Benchmark	% <90 Day Total Time Benchmark		Average Total Time (Days)	Average Research Office Time	Average Researcher Time		
BLLBRRY	20	18	90%	55	25	30	3.3
CINSW	21	17	81%	84	31	53	1.4
HNELHD	35	29	83%	86	28	58	2.1
ISLHD	6	5	83%	72	44	29	1.2
JHFMHN	1	0	0%	602	38	564	2.0
NBMLHD	9	8	89%	70	38	31	1.4
NNSWLHD	3	2	67%	232	57	175	3.0
NSLHD	5	4	80%	56	25	31	1.6
SCHN	14	11	79%	110	28	82	1.5
SESLHD	13	13	100%	38	25	13	2.5
SLHD-CCD	17	8	47%	121	26	95	2.1
SLHD-RPA	57	47	82%	68	15	53	1.5
SVHN	38	32	84%	64	26	38	1.2
SWSLHD	22	20	91%	63	19	44	1.8
WNSWLHD	11	11	100%	11	32	13	1.4
WSLHD	32	25	78%	61	32	29	1.6
TOTAL	304	250	82%	75	26	49	1.8

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) between 01/07/2021 and 30/09/2021.

Ethics Approval (Q3 2021)							
Clinical Trials							
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)		Count Request for Information
		Count <90 Day Benchmark	% <90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time	
BLLBRRY	20	18	90%	55	25	30	3.3
CINSW	1	1	100%	23	21	2	1.0
HNELHD	3	2	67%	116	36	80	2.0
ISLHD	1	0	0%	99	48	51	1.0
JHFMHN	0	0	-	-	-	-	-
NBMLHD	1	1	100%	64	42	22	2.0
NNSWLHD	0	0	-	-	-	-	-
NSLHD	4	3	75%	57	25	31	1.5
SCHN	6	5	83%	122	32	90	1.2
SESLHD	3	3	100%	40	31	8	1.3
SLHD-CCD	3	1	33%	101	32	69	1.7
SLHD-RPA	19	17	89%	58	12	45	1.7
SVHN	15	13	87%	71	27	44	1.3
SWSLHD	3	3	100%	44	21	23	1.7
WNSWLHD	0	0	-	-	-	-	-
WSLHD	12	9	75%	66	31	35	1.8
TOTAL	91	76	84%	67	25	42	1.9

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) between 01/07/2021 and 30/09/2021 **by sponsor type**

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
BLLBRRY	-	-	-	16	24	48	4	29	82
CINSW	-	-	-	-	-	-	1	21	23
HNELHD	1	52	217	-	-	-	2	29	66
ISLHD	1	48	99	-	-	-	-	-	-
NBMLHD	-	-	-	-	-	-	1	42	64
NSLHD	-	-	-	1	23	55	3	26	57
SCHN	-	-	-	3	32	78	3	33	166
SESLHD	1	24	33	-	-	-	2	35	43
SLHD-CCD	-	-	-	2	34	131	1	29	40
SLHD-RPA	3	23	118	3	8	33	13	11	50
SVHN	2	22	31	8	23	60	5	35	105
SWSLHD	1	27	53	2	18	40	-	-	-
WSLHD	1	33	53	6	31	61	5	32	74
Total	10	30	87	41	24	57	40	25	72

Table 4. Quarterly **clinical trial approvals** (greater than low risk) between 01/01/2021 and 30/09/2021, **by sponsor type**

Sponsor Type	Q1 2021			Q2 2021			Q3 2021		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	2	26	52	7	22	152	10	30	87
Commercial Entity	40	29	93	24	24	62	41	24	57
Investigator Initiated	29	38	103	49	24	80	40	25	72
Total	71	33	96	80	24	81	91	25	67

Table 5. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications (greater than low risk) between 01/01/2021 and 30/09/2021.

NSW PHOs	Q1 2021							Q2 2021							Q3 2021						
	Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
		Count 45 Day Benchmark	% 45 Day Benchmark	Average Metric 3 Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Metric 3 Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Metric 3 Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	16	13	81%	28	10	63%	77	13	13	100%	21	11	85%	50	20	19	95%	25	18	90%	55
CINSW	9	9	100%	30	4	44%	86	16	16	100%	29	13	81%	72	21	21	100%	31	17	81%	84
HNELHD	27	21	78%	35	13	48%	96	27	24	89%	27	20	74%	76	35	33	94%	28	29	83%	86
ISLHD	8	3	38%	73	3	38%	127	2	0	0%	46	1	50%	178	6	4	67%	44	5	83%	72
JHFMHN	2	0	0%	303	0	0%	291	3	1	33%	46	1	33%	122	1	1	100%	38	0	0%	602
NBMLHD	5	5	100%	33	4	80%	82	10	9	90%	35	9	90%	69	9	7	78%	38	8	89%	70
NNSWLHD	5	3	60%	34	2	40%	91	1	1	100%	25	1	100%	66	3	1	33%	57	2	67%	232
NSLHD	16	15	94%	31	11	69%	84	22	21	95%	22	16	73%	82	5	5	100%	25	4	80%	56
SCHN	21	21	100%	28	10	48%	97	12	11	92%	29	9	75%	93	14	12	86%	28	11	79%	110
SESLHD	10	5	50%	44	4	40%	104	12	7	58%	50	5	42%	142	13	12	92%	25	13	100%	38
SLHD-CCD	11	11	100%	17	7	64%	89	9	9	100%	23	5	56%	85	17	17	100%	26	8	47%	121
SLHD-RPA	31	30	97%	16	15	48%	95	47	47	100%	14	33	70%	79	57	56	98%	15	47	82%	68
SVHN	22	16	73%	40	7	32%	116	18	14	78%	33	14	78%	79	38	36	95%	26	32	84%	64
SWSLHD	26	21	81%	35	11	42%	107	21	21	100%	25	16	76%	88	22	22	100%	19	20	91%	63
WNSWLHD	3	1	33%	51	2	67%	90	3	1	33%	56	2	67%	105	11	10	91%	32	11	100%	11
WSLHD	17	17	100%	27	14	82%	67	19	19	100%	26	15	79%	67	32	30	94%	32	25	78%	61
TOTAL	229	191	83%	28	117	51%	83	235	214	91%	26	171	73%	82	304	286	94%	26	250	82%	75



KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Site-specific assessment (SSA) applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> • Study Type = All • Application Type = Greater than low risk • Approval Type = “Authorised” or “authorised with conditions” within the reporting period
Exclusions	<ul style="list-style-type: none"> • Application Type = Low and negligible risk • Approval Type = Not within the reporting period • Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary for Metric 4:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised between 01/07/2021 and 30/09/2021 (Quarter 3 2021) are shown in **Table 6**. In Quarter 3 2021, **471** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **65 days**. Of these 471 studies, **209** (44%) were classified as clinical trials (**Table 7**). Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8 (by NSW PHOs)** and **Table 9 (by quarter)**. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) between 01/07/2021 – 30/09/2021.

SSA Approvals (Q3 2021)								
All greater than low risk applications								
NSW PHOs	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of <60 Day Benchmark	% <60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	0	0	-	-	-	-	-	-
CCLHD	7	4	57%	130	25	17	0	88
FWLHD	0	0	-	-	-	-	-	-
HNELHD	43	37	86%	37	7	17	1	14
ISLHD	18	16	89%	34	5	9	1	21
JHFMHN	0	0	-	-	-	-	-	-
MLHD	4	4	100%	19	6	6	1	8
MNCLHD	5	1	20%	189	13	12	3	163
NBMLHD	19	10	53%	102	21	11	5	69
NNSWLHD	6	4	67%	56	21	2	6	34
NSLHD	26	18	69%	64	6	11	2	47
NSWHPH	11	6	55%	80	13	33	0	34
SCHN	35	19	54%	68	10	24	0	34
SESLHD	44	30	68%	57	7	19	3	30
SLHD-CCD	20	13	65%	61	9	26	0	25
SLHD-RPA	45	33	73%	49	7	12	3	30
SNSWLHD	6	4	67%	52	41	11	35	0
SVHN	33	23	70%	61	10	10	0	42
SWSLHD	64	40	63%	103	5	21	0	77
WNSWLHD	14	14	100%	10	1	7	0	1
WSLHD	71	59	83%	62	9	8	2	45
TOTAL	471	335	71%	65	9	15	2	41

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) between 01/07/2021 and 30/09/2021.

SSA Approvals (Q3 2021)								
Clinical Trials								
NSW PHOs	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of <60 Day Benchmark	% <60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	0	0	-	-	-	-	-	-
CCLHD	2	2	100%	30	21	5	0	5
FWLHD	0	0	-	-	-	-	-	-
HNELHD	14	13	93%	20	8	8	1	4
ISLHD	11	10	91%	33	6	11	1	16
JHFMHN	0	0	-	-	-	-	-	-
MLHD	1	1	100%	7	6	1	0	0
MNCLHD	3	1	33%	65	19	16	4	30
NBMLHD	9	7	78%	73	25	10	3	38
NNSWLHD	2	2	100%	49	46	1	11	2
NSLHD	20	14	70%	59	6	10	2	42
NSWHPTH	0	0	-	-	-	-	-	-
SCHN	20	10	50%	75	10	28	0	37
SESLHD	16	12	75%	39	12	14	0	13
SLHD-CCD	12	7	58%	79	12	37	0	31
SLHD-RPA	21	15	71%	58	13	12	6	34
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	17	10	59%	66	14	9	0	43
SWSLHD	24	20	83%	39	4	11	0	24
WNSWLHD	4	4	100%	19	2	17	0	0
WSLHD	33	30	91%	55	8	9	3	38
TOTAL	209	158	76%	53	10	13	2	29

Table 8. NSW PHO performances in SSA approvals (greater than low risk) between 01/07/2021 and 30/09/2021, by sponsor type

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
CCLHD	1	29	45	1	12	15	-	-	-
HNELHD	2	13	13	6	9	28	6	7	14
ISLHD	6	6	42	5	6	23	-	-	-
MLHD	-	-	-	-	-	-	1	6	7
MNCLHD	1	21	68	1	10	28	1	26	99
NBMLHD	3	14	42	4	20	46	2	54	173
NNSWLHD	-	-	-	2	46	49	-	-	-
NSLHD	6	5	64	8	7	36	6	7	84
SCHN	7	5	50	9	12	71	4	15	126
SESLHD	3	11	35	9	13	39	4	11	43
SLHD-CCD	1	10	28	7	12	46	4	12	151
SLHD-RPA	3	22	44	4	14	48	14	11	64
SVHN	5	15	37	7	13	61	5	13	102
SWSLHD	6	5	85	13	4	23	5	3	25
WNSWLHD	3	2	7	1	0	53	-	-	-
WSLHD	1	13	30	23	8	23	9	8	138
Total	48	9	47	100	10	37	61	11	84

Table 9. Quarterly SSA approvals (greater than low risk applications) approved between 01/01/2021 and 30/09/2021, by sponsor type

Sponsor Type	Q1 2021			Q2 2021			Q3 2021		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	32	14	91	43	9	75	48	9	47
Commercial Entity	114	10	45	112	9	39	100	10	37
Investigator Initiated	66	14	72	86	11	105	61	11	84
Total	212	12	61	241	10	69	209	10	53

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) between 01/01/2021 and 30/09/2021.

NSW PHOs	Q1 2021							Q2 2021							Q3 2021						
	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average Metric 4 Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average Metric 4 Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average Metric 4 Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	1	1	100%	0	0	0%	76	3	3	100%	6	3	100%	11	0	0	-	-	0	-	-
CALVARY	13	8	62%	14	12	92%	29	9	6	67%	15	9	100%	17	0	0	-	-	0	-	-
CCLHD	14	3	21%	29	6	43%	79	12	9	75%	18	8	67%	70	7	2	29%	25	4	57%	130
FWLHD	0	0	-	-	0	-	-	2	1	50%	10	2	100%	14	0	0	-	-	0	-	-
HNELHD	42	13	31%	28	28	67%	63	33	20	61%	14	26	79%	40	43	40	93%	7	37	86%	37
ISLHD	13	13	100%	6	7	54%	63	17	14	82%	8	12	71%	89	18	16	89%	5	16	89%	34
JHFMHN	3	1	33%	52	1	33%	114	1	1	100%	8	1	100%	19	0	0	-	-	0	-	-
MLHD	1	0	0%	45	0	0%	109	5	5	100%	6	5	100%	13	4	4	100%	6	4	100%	19
MNCLHD	6	2	33%	22	5	83%	46	9	5	56%	21	7	78%	71	5	3	60%	13	1	20%	189
NBMLHD	17	12	71%	13	8	47%	104	21	12	57%	15	9	43%	114	19	9	47%	21	10	53%	102
NNSWLHD	6	5	83%	6	4	67%	64	2	1	50%	12	2	100%	12	6	3	50%	21	4	67%	56
NSLHD	32	29	91%	8	16	50%	89	39	37	95%	6	24	62%	71	26	26	100%	6	18	69%	64
NSWHPTH	9	7	78%	13	1	11%	143	6	4	67%	13	1	17%	135	11	7	64%	13	6	55%	80
SCHN	18	16	89%	7	8	44%	74	32	26	81%	14	14	44%	105	35	27	77%	10	19	54%	68
SESLHD	54	49	91%	5	41	76%	44	41	37	90%	6	31	76%	46	44	37	84%	7	30	68%	57
SLHD-CCD	14	13	93%	5	12	86%	85	29	29	100%	6	18	62%	66	20	18	90%	9	13	65%	61
SLHD-RPA	26	21	81%	7	17	65%	70	46	36	78%	11	34	74%	51	45	37	82%	7	33	73%	49
SNSWLHD	0	0	-	-	0	-	-	2	0	0%	55	0	0%	108	6	3	50%	41	4	67%	52
SVHN	24	18	75%	12	12	50%	75	32	23	72%	13	23	72%	62	33	25	76%	10	23	70%	61
SWSLHD	64	60	94%	7	29	45%	105	62	61	98%	4	40	65%	87	64	63	98%	5	40	63%	103
WNSWLHD	6	6	100%	1	5	83%	19	8	7	88%	5	5	63%	117	14	14	100%	1	14	100%	10
WSLHD	76	72	95%	8	47	62%	70	76	69	91%	9	48	63%	76	71	66	93%	9	59	83%	62
TOTAL	439	349	79%	11	259	59%	75	487	406	83%	10	322	66%	71	471	400	85%	9	335	71%	65

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

Tel (02) 9391 9920 | james.cokayne@health.nsw.gov.au

Yagiz Aksoy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

Tel (02) 9461 7887 | yagiz.aksoy@health.nsw.gov.au